Business Context and Reporting Period
This Form 8-K Current Report was filed by Corvus Pharmaceuticals, Inc. (CRVS) on April 22, 2026. The report discloses changes to the composition of the Board of Directors, effective April 23, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Board Appointment: Andrew C. Chan, M.D., Ph.D., was appointed to the Board of Directors as a Class II director. His term expires at the 2027 annual meeting of stockholders.
- Committee Assignment: Dr. Chan was appointed to the Nominating and Corporate Governance Committee.
- Board Resignation: Scott Morrison resigned from the Board of Directors. Mr. Morrison served on the Board for over a decade and was the Chairperson of the Audit Committee.
Compensation and Governance Details
Dr. Chan's compensation package includes:
- Cash Retainer: $35,000 annual retainer for Board service, earned quarterly and prorated for the remainder of the current quarter.
- Committee Fee: Additional $4,000 annual cash compensation for service on the Nominating Committee, earned quarterly and prorated.
- Equity Grant: An automatic initial grant of a stock option to purchase 30,000 shares of Common Stock under the 2016 Equity Incentive Award Plan.
- Indemnification: Dr. Chan will enter into the Company's standard indemnification agreement for directors and executive officers.
Investor Verification Checklist
- Verify the qualifications and background of the new director, Andrew C. Chan, M.D., Ph.D.
- Review the Company's 2016 Equity Incentive Award Plan to understand the terms of the 30,000-share option grant.
- Confirm the status of the Audit Committee following the resignation of its Chairperson, Scott Morrison.
- Check for any subsequent filings regarding the election of a new Audit Committee Chairperson.